{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:57:06Z","timestamp":1772013426337,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jgar.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T19:31:54Z","timestamp":1499369514000},"page":"326-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["In vitro activity of ceftolozane\/tazobactam in combination with other classes of antibacterial agents"],"prefix":"10.1016","volume":"10","author":[{"given":"C\u00e9dric","family":"Jacqueline","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Howland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Chesnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2017.04.003_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with Gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2017.04.003_bib0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.mib.2011.08.003","article-title":"Combination therapies for combating antimicrobial resistance","volume":"14","author":"Fischbach","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.jgar.2017.04.003_bib0015","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.003_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2017.04.003_bib0025","series-title":"Zerbaxa (ceftolozane and tazobactam) prescribing information","author":"Merck Sharp & Dohme, Corp","year":"2015"},{"key":"10.1016\/j.jgar.2017.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.04.003_bib0035","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2017.04.003_bib0040","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/jcp.15.4.328","article-title":"Methods of testing combined antibiotic bactericidal action and the significance of the results","volume":"15","author":"Garrod","year":"1962","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jgar.2017.04.003_bib0045","series-title":"Antibiotics in laboratory medicine","author":"Lorian","year":"2005"},{"key":"10.1016\/j.jgar.2017.04.003_bib0050","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1128\/AAC.01666-15","article-title":"Daptomycin in combination with ceftolozane\u2013tazobactam or cefazolin against daptomycin-susceptible and -nonsusceptible Staphylococcus aureus in an in vitro, hollow-fiber model","volume":"60","author":"Smith","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.003_bib0055","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.50.5.1633-1641.2006","article-title":"Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates","volume":"50","author":"Quale","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.003_bib0060","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1128\/AAC.00574-09","article-title":"Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa","volume":"53","author":"Rodriguez-Martinez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.003_bib0065","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.003_bib0070","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.003_bib0075","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1128\/AAC.01452-08","article-title":"In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including \u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"53","author":"Vidaillac","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.003_bib0080","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ijantimicag.2014.07.023","article-title":"Microbiological interaction studies between ceftazidime\u2013avibactam and pulmonary surfactant and between ceftazidime\u2013avibactam and antibacterial agents of other classes","volume":"44","author":"Dallow","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.04.003_bib0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40121-016-0141-y","article-title":"In vitro activity of ceftolozane\/tazobactam alone or with an aminoglycoside against multi-drug-resistant Pseudomonas aeruginosa from pediatric cystic fibrosis patients","volume":"6","author":"Dassner","year":"2017","journal-title":"Infect Dis Ther"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517300838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517300838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T14:20:17Z","timestamp":1535638817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517300838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":17,"alternative-id":["S2213716517300838"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2017.04.003","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftolozane\/tazobactam in combination with other classes of antibacterial agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}